Doesn't the now exposed via MSM Biden family criminal enterprise, necessarily also expose the complicit criminality of ALL USA and FVEY+ Intel and LEO agencies, their financial institutional partners, the MSM, the congress, and every other in-the-know government and supragovernmental organization (UN, WEF, etc)?
If you profit from someone else's crimes? - RICO
If you know of crimes and take no action under your chartered purpose and jurisdiction? - RICO
o7
The other guy said he was the chosen one, king of the jews, had nothing to repent for, has great and unmatched wisdom, has read a poem called the snake multiple times in public,etc…
He does not deny that.
"Shawn Ryan is the founder of Vigilance Elite and the creator and host of the hit podcast "The Shawn Ryan Show." Ryan, himself a former US Navy Seal and CIA Contractor with 14 years of service spanning multiple combat operations, developed the series to document the untold stories of war, loss, and redemption from the men and women who lived them."
https://shawnryanshow.com/pages/bio
https://www.kalebhouse.org/about-kaleb-house
Contracted by DARPA in 2013 to make the mrna gene editing technology. In other words, the US govt and citizen tax dollars affected genocide and genetically engineered immunocompromise. According to a plan.
Pfizer AND moderna were contracted assets for the US MILITARY via darpa, aka the DOD and US gov't. In 2013. For mrna bio-nano technology
darpa Awards moderna therapeutics A Grant For Up to $25 Million to Develop Messenger RNA therapeutics™ (2013)
https://www.prnewswire.com/news-releases/darpa-awards-moderna-therapeutics-a-grant-for-up-to-25-million-to-develop-messenger-rna-therapeutics-226115821.html
CAMBRIDGE, Mass., Oct. 2, 2013 /PRNewswire/ - moderna Therapeutics, the company pioneering messenger RNA therapeutics™, a revolutionary new treatment modality to enable the in vivo production of therapeutic proteins, announced today that the Defense Advanced Research Projects Agency (darpa) has awarded the company up to $25 million to research and develop its messenger RNA therapeutics™ platform as a rapid and reliable way to make antibody-producing drugs to protect against a wide range of known and unknown emerging infectious diseases and engineered biological threats.
Messenger RNA therapeutics™ can be designed to tap directly into the body's natural processes to produce antibodies without exposing people to a weakened or inactivated virus or pathogen, as is the case with the vaccine approaches currently being tested. As a result, moderna's messenger RNA therapeutics™ platform has the potential to speed the development and manufacture of treatments that can produce a safer, more reliable and more robust immune response than existing technologies.
"We are honored to be chosen by darpa for this important grant, which will greatly accelerate our efforts to develop antibody messenger RNA therapeutics™ to combat a wide range of infectious diseases," said Stephane Bancel, president and founding CEO of moderna. "We were awarded this major grant after an intense and rigorous scientific review, and it is a testament to our team's progress and to the profound implications of messenger RNA therapeutics™ that our work was funded. We look forward to further expanding the development of our platform into this critically important new therapeutic area."
This $24.6 million grant could support research for up to 5 years to advance promising antibody- producing drug candidates into preclinical testing and human clinical trials. The company also received a $0.7 million "seedling" grant from darpa in March to begin work on the project.
This grant is part of a darpa program called ADEPT: PROTECT (Autonomous Diagnostics to Enable Prevention and Therapeutics: Prophylactic Options to Environmental and Contagious). The goal is to develop platform technologies that can be deployed safely and rapidly to provide the U.S. population with near-immediate protection against emerging infectious diseases and engineered biological weapons, even in cases when the pathogen or infectious agent is unknown.
Pfizer Awarded darpa Biodefense Contract - DoD Daily Contracts 2013
https://news.clearancejobs.com/2013/12/04/pfizer-awarded-darpa-biodefense-contract-dod-daily-contracts/
Pfizer, Inc., has been awarded a $7,670,632 technology investment agreement. Pfizer shall perform a research and development program designed to develop a technology platform to identify and subsequently induce the production of protective antibodies to an emerging pathogen directly in an infected or exposed individual. Work will be performed in Cambridge, Mass. The estimated completion date is Dec. 8, 2016. Fiscal 2013 research and development funds are being obligated at time of award. The contracting activity is the Defense Advanced Research Projects Agency, Arlington, Va., (HR0011-14-3-0001).